K
Krikor Bornazyan
Researcher at University of California, Los Angeles
Publications - 8
Citations - 1240
Krikor Bornazyan is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Pembrolizumab & Common Terminology Criteria for Adverse Events. The author has an hindex of 5, co-authored 8 publications receiving 868 citations. Previous affiliations of Krikor Bornazyan include UCLA Medical Center.
Papers
More filters
Journal ArticleDOI
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian,Aaron Lisberg,Krikor Bornazyan,Darlene Veruttipong,Jonathan W. Goldman,Silvia C. Formenti,Edward B. Garon,Percy Lee +7 more
TL;DR: This trial aimed to assess disease control and pulmonary toxicity in patients who previously received radiotherapy for non-small-cell lung cancer (NSCLC) before receiving pembrolizumab to determine whether previous radiotherapy affected progression-free survival, overall survival, and pulmonaryoxicity in the intention-to-treat population.
Journal ArticleDOI
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
Aaron Lisberg,Amy L. Cummings,Jonathan W. Goldman,Krikor Bornazyan,Nicholas Dean Reese,T. Wang,P. Coluzzi,Blanca A. Ledezma,Melody A. Mendenhall,Jaime Hunt,Brian R. Wolf,Benjamin P Jones,John Madrigal,John M. Horton,Marshall L. Spiegel,James M. Carroll,Jaklin Gukasyan,T. Williams,Lauren Sauer,Courtney L. Wells,Ariana R. Hardy,Paulina J Linares,C. Lim,L. Ma,Carlos R. Adame,Edward B. Garon +25 more
TL;DR: Pembrolizumab’s lack of efficacy in TKI naïve, PD‐L1+, EGFR‐mutant patients with advanced NSCLC, including those with PD‐ L1 expression ≥50%, suggests that it is not an appropriate therapeutic choice in this setting.
Journal ArticleDOI
Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center.
Aaron Lisberg,D. Andrew Tucker,Jonathan W. Goldman,Brian R. Wolf,James M. Carroll,Ariana R. Hardy,Karolyn K. Morris,Paulina J Linares,Carlos R. Adame,Marshall L. Spiegel,Courtney L. Wells,Jordan R. McKenzie,Blanca A. Ledezma,Melody A. Mendenhall,Phillip A. Abarca,Krikor Bornazyan,Jaime Hunt,Nima Moghadam,Natalie Chong,Danielle J. Nameth,Caitlin Marx,John Madrigal,Sitaram Vangala,Narek Shaverdian,David Elashoff,Edward B. Garon +25 more
TL;DR: It is revealed that treatment-related adverse events predicted for improved clinical outcome with pembrolizumab, and when controlling for guarantee-time bias and plausible confounders, this association remained.
Journal ArticleDOI
A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naïve patients with advanced NSCLC.
Aaron Lisberg,Amy L. Cummings,Jonathan W. Goldman,Krikor Bornazyan,Nicholas Dean Reese,Tina Wang,Paul Coluzzi,Blanca A. Ledezma,Melody A. Mendenhall,Benjamin P Jones,John Madrigal,James M. Carroll,Jaklin Gukasyan,Tawny Williams,Lauren Sauer,Courtney L. Wells,Ariana R. Hardy,Paulina J Linares,Carlos R. Adame,Edward B. Garon +19 more
TL;DR: This clinical benefit has been less frequently observed in patients whose tumors harbor pembrolizumab-positive cells, and this data indicates that further studies are needed to establish a causative mechanism behind this decline.
Journal ArticleDOI
Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation
Charlene M. Fares,Timothy Williamson,Matthew K. Theisen,Amy L. Cummings,Krikor Bornazyan,James M. Carroll,Marshall L. Spiegel,Annette L. Stanton,Edward B. Garon +8 more
TL;DR: Findings suggest that EMR notes and AE logs may not be reliable sources for capturing physical and psychological symptoms experienced by patients with lung cancer, supporting use of PRO assessments in oncology practices.